title: Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro.
abstract: Microglia mediate multiple facets of neuroinflammation, including cytotoxicity, repair, regeneration, and immunosuppression due to their ability to acquire diverse activation states, or phenotypes. Modulation of microglial phenotype is an appealing neurotherapeutic strategy but a comprehensive study of classical and more novel microglial phenotypic markers in vitro is lacking. The aim of this study was to outline the temporal expression of a battery of phenotype markers from polarised microglia to generate an in vitro tool for screening the immunomodulatory potential of novel compounds. We characterised expression of thirty-one macrophage/microglial phenotype markers in primary microglia over time (4, 12, 36, and 72 h), using RT-qPCR or multiplex protein assay. Firstly, we selected Interleukin-4 (IL-4) and lipopolysaccharide (LPS) as the strongest M1-M2 polarising stimuli, from six stimuli tested. At each time point, markers useful to identify that microglia were M1 included iNOS, Cox-2 and IL-6 and a loss of M2a markers. Markers useful for quantifying M2b-immunomodulatory microglia included, increased IL-1RA and SOCS3 and for M2a-repair and regeneration, included increased arginase-1, and a loss of the M1 and M2b markers were discriminatory. Additional markers were regulated at fewer time points, but are still likely important to monitor when assessing the immunomodulatory potential of novel therapies. Further, to facilitate identification of how novel immunomodulatory treatments alter the functional affects of microglia, we characterised how the soluble products from polarised microglia affected the type and rate of neuronal death; M1/2b induced increasing and M2a-induced decreasing neuronal loss. We also assessed any effects of prior activation state, to provide a way to identify how a novel compound may alter phenotype depending on the stage of injury/insult progression. We identified generally that a prior M1/2b reduced the ability of microglia to switch to M2a. Altogether, we have characterised a profile of phenotype markers and a mechanism of assessing functional outcome that we can use as a reference guide for first-line screening of novel immunomodulatory therapies in vitro in the search for viable neuroprotectants.
authors: Inserm, U676, Paris, France.
authors: Vibol
authors: V
authors: Chhor
authors: Tifenn
authors: T
authors: Le Charpentier
authors: Sophie
authors: S
authors: Lebon
authors: Marie-Virgine
authors: MV
authors: Oré
authors: Idoia Lara
authors: IL
authors: Celador
authors: Julien
authors: J
authors: Josserand
authors: Vincent
authors: V
authors: Degos
authors: Etienne
authors: E
authors: Jacotot
authors: Henrik
authors: H
authors: Hagberg
authors: Karin
authors: K
authors: Sävman
authors: Carina
authors: C
authors: Mallard
authors: Pierre
authors: P
authors: Gressens
authors: Bobbi
authors: B
authors: Fleiss
mesh_terms: D000818:Animals; D016764:Cell Polarity; D002470:Cell Survival / Q000502:physiology; D002540:Cerebral Cortex / Q000166:cytology; D018925:Chemokines / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D007150:Immunohistochemistry; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D051379:Mice; D017628:Microglia / Q000473:pathology*; D009474:Neurons / Q000502:physiology; D010641:Phenotype; D061251:Primary Cell Culture; D012313:RNA / Q000096:biosynthesis / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D051197:Toll-Like Receptor 4 / Q000378:metabolism
chemical_list: D018925:Chemokines; D016207:Cytokines; D008070:Lipopolysaccharides; D051197:Toll-Like Receptor 4; D012313:RNA